Tag Archives: IPR

225th Anniversary of First U.S. Patent

admin-ajax

225 years ago last Friday the first U.S. patent was issued to Samuel Hopkins for an improved process for creating potash, America’s first industrial chemical compound. America’s Founding Fathers recognized Intellectual property as a fundamental right, so much so they enshrined it into our Constitution. The systems for issuing patents have changed over the years, but Congress retains the authority to regulate and change matters of patent law. Unfortunately, not all changes to patent law Read More >

Patently BIOtech  |  Leave a comment  |  Email This Post
Tags: , , , , , , , , ,

CNBC Commentary: Hedge funds, ‘reverse trolls’ crushing biopharma innovation

Vote No on HR 9

Patents are the lifeblood of medical innovation. They are the cornerstone that enables companies to perform the long and costly research and development for cures and therapies to combat devastating diseases such as cancer, HIV and Alzheimer’s. Unfortunately, the system that helps protect these innovations is being abused by outside interests. BIO and others have called upon Congress to fix these problems as part of a greater patent reform debate. Today one more voice joined Read More >

Patently BIOtech  |  Leave a comment  |  Email This Post
Tags: , , , ,

IP Sessions at BIO 2015: The Impact of the Inter Partes Review on (BIO)Pharma

patent

The Intellectual Property Track at the BIO International Convention was a chance for IP thought leaders in the biotech sector to discuss some of the most pressing issues impacting the industry. Let’s recap what we learned from one of the IP sessions at BIO 2015: The Impact of IPRs on (BIO)Pharma On Tuesday, patent litigation experts met to discuss inter partes review proceedings and how they are impacting biotechnology. Panelists from The Impact of IPRs Read More >

Patently BIOtech  |  Leave a comment  |  Email This Post
Tags: , , , , , , , , , , , , , , , , , , , ,

Sen Menendez Asks SEC to Investigate IPR Abuses

Securities and Exchange Commission

New Jersey Senator Bob Menendez has asked the Securities and Exchange Commissioner (SEC) to investigate a new investment scheme designed to manipulate the stock prices of companies engaged in research and development of innovative medical therapies, to determine if the practice is illegal. As reported in this Bloomberg Business article, certain investment firms are shorting the stocks of patent-dependent life sciences companies and then using new patent litigation procedures to challenge their patents and drive Read More >

Public Policy  |  Leave a comment  |  Email This Post
Tags: , , , , , , , , ,

IP Sessions at the 2015 BIO International Convention

BIO International Convention

This year’s BIO International Convention will be host to educational sessions on the latest issues in the biotech IP sector.  The world’s largest biotechnology gathering, the convention offers attendees the chance to come together to hear, discuss, and learn about current issues affecting the biotech community. Here’s a look at the Intellectual Property Track at this year’s convention: Sessions* Intellectual Property Opening Plenary Antibody Therapeutics: May I Have Them All? The Impact of USPTO Inter Read More >

Patently BIOtech  |  Leave a comment  |  Email This Post
Tags: , , , , , , , , , , , , , ,